VolitionRx Limited (NYSE:VNRX) Q4 2021 Results Conference Call March 31, 2022 8:00 AM ET
Company Participants
Scott Powell - Executive Vice President of Investor Relations
Cameron Reynolds - President and Chief Executive Officer
Terig Hughes - Chief Financial Officer
Tom Butera - Chief Executive Officer, Volition Veterinary Diagnostics Development
Conference Call Participants
Ross Osborn - Cantor Fitzgerald
Bruce Jackson - The Benchmark Company
Nathan Weinstein - Aegis Capital
Michael Okunewitch - Maxim
Operator
Good morning, ladies and gentlemen. Thank you for standing by. Welcome to VolitionRx Limited's Fourth Quarter and Full Year 2021 Earnings Conference Call. [Operator Instructions] This conference is being recorded today, March 31, 2022.
I would now like to turn the conference call over to Scott Powell, Executive Vice President of Investor Relations. Please go ahead.
Scott Powell
Thank you, and welcome, everyone, to today's earnings conference call for VolitionRx Limited. This call will cover Volition's financial and operating results for the fourth quarter and full year of 2021, along with a discussion of our recent activities and key upcoming milestones. Following our prepared remarks, we will open the conference call to a question-and-answer session.
Also on our call today are Mr. Cameron Reynolds, President and Chief Executive Officer; Mr. Terig Hughes, Chief Financial Officer; and Dr. Tom Butera, Chief Executive Officer of our Volition Veterinary subsidiary.
Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our beliefs as well as assumptions we have used based upon information currently available to us.
Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties and assumptions. Actual future results may vary significantly based on
- Read more current VNRX analysis and news
- View all earnings call transcripts